OS in the whole cohort was analyzed separately according to the patient's peripheral blood CRP levels (taken within +/− 4 weeks from tumor sampling used for PD‐L1 analysis) and tumor PD‐L1 TPS score (Figure 1A,B). This evidence concerns the gene CRP and neoplasm.